XML 22 R22.htm IDEA: XBRL DOCUMENT v3.2.0.727
Collaboration and License Agreements, Les Laboratoires Servier (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Sep. 30, 2012
Nov. 30, 2011
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Dec. 31, 2014
License And Collaboration Agreements [Line Items]              
Deferred revenue included in current liabilities     $ 10,186,000   $ 10,186,000   $ 14,248,000
Deferred revenue included in long-term liabilities     12,722,000   $ 12,722,000   16,472,000
Servier [Member] | Servier MGA271 [Member]              
License And Collaboration Agreements [Line Items]              
Collaboration agreement date         November 2011    
Non-refundable upfront payment   $ 20,000,000          
Additional license grant fees     30,000,000   $ 30,000,000    
Additional Potential Clinical Milestone Payments Under Agreement     47,000,000   47,000,000    
Additional Potential Regulatory Milestone Payments Under Agreement     140,000,000   140,000,000    
Additional Potential Sales Milestone Payments Under Agreement     208,000,000   $ 208,000,000    
Original period of development         27 months    
Expected period of development         42 months    
Recognized revenue under agreement     21,000 $ 200,000 $ 100,000 $ 400,000  
Deferred revenue     14,000   $ 14,000   100,000
Servier [Member] | Servier DART [Member]              
License And Collaboration Agreements [Line Items]              
Collaboration agreement date         September 2012    
Non-refundable upfront payment $ 20,000,000            
Additional license grant fees     65,000,000   $ 65,000,000    
Additional Potential Clinical Milestone Payments Under Agreement     98,000,000   98,000,000    
Additional Potential Regulatory Milestone Payments Under Agreement     300,000,000   300,000,000    
Additional Potential Sales Milestone Payments Under Agreement     630,000,000   $ 630,000,000    
Original period of development         29 months    
Expected period of development         75 months    
Recognized revenue under agreement     1,000,000 $ 2,700,000 $ 1,800,000 10,000,000  
Deferred revenue     16,000,000   16,000,000   17,700,000
License option fees received           15,000,000  
Clinical milestone payments received under agreement           $ 5,000,000  
Offset to research and development costs under collaboration arrangement     200,000   $ 500,000    
Expected development period         82 months    
Clinical milestone payments per IND     5,000,000   $ 5,000,000    
Review period         30 days    
Deferred revenue included in current liabilities     3,300,000   $ 3,300,000   3,300,000
Deferred revenue included in long-term liabilities     $ 12,700,000   $ 12,700,000   $ 14,400,000